Last edition
News about "Drugs Controller General of India "
No Physical Applications For WHO-GMP (COPP) Approvals After August 15: CDSCO
The Drugs Controller General of India has directed all zonal and sub-zonal offices of the Central Drugs Standard Control Organization (CDSCO) to stop accepting physical applications for WHO-GMP (Certificate of Pharmaceutical Product – COPP) after August 15, 2025.
Drugs Controller General Of India | 08/08/2025 | By Dineshwori | 141
Akums Becomes First Indian CDMO to Receive DCGI Approval for Innovative Glaucoma Treatment
Glaucoma ranks as the second leading cause of irreversible but preventable blindness worldwide, with India contributing to 23.5 percent of the global burden.
Drugs Controller General Of India | 01/04/2025 | By Abha | 286
CDSCO Launches Digital Portal to Simplify Extension Process for Pharma MSMEs
This initiative is integrated into the Online National Drugs Licensing System (ONDLS) and follows the Health Ministry's notification granting an extension for compliance with updated Good Manufacturing Practices (GMP).
Drugs Controller General Of India | 26/03/2025 | By Aishwarya | 263
Akums Combines Two Potent Diabetes Medicines for Enhanced Treatment Efficacy
Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, aids in eliminating excess glucose via urine while delivering additional benefits such as improved cardiovascular and renal outcomes, along with better weight management.
Drugs Controller General Of India | 03/02/2025 | By Aishwarya | 291
Orchid Pharma Gets DCGI Approval for Enmetazobactam
Orchid Pharma has secured Drugs Controller General of India (DCGI) approval for the manufacturing and marketing of its invented New Chemical Entity Active Pharmaceutical Ingredient (API), Enmetazobactam.
Drugs Controller General Of India | 10/06/2024 | By Aishwarya | 392
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy